Shots: The accelerated approval is based on P-Ib/II GO29365 study results involves assessing of Polivy + bendamustine + Rituxan (BR)/Gazyva (obinutuzumab) vs BR in patients with r/r follicular lymphoma or DLBCL with 2L+ treatment The P-Ib/II GO29365 study results: CRR (40% vs 18%); objective response (45% vs 18%); DOR lasting at least 6mos. (64% vs […]Read More
Shots: The ZUMA-1 trial involves assessing of Yescarta in patients with refractory large B-cell lymphoma for a duration of two years ZUMA-1 trial results (N=101): OR 83%; CR 58%; median follow up @27.1, 24 mos. (39%, 93% remain in response); mDOR 11.1 mos.; with no new safety signals observed Yescarta (axicabtagene ciloleucel) is novel CAR […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
